Skip to main content

Table 4 The signal value per preferred term of GERD-like symptoms of GLP-1-RAs and DPP-4-Is

From: Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database

AE GLP-1-RAs (n1+ = 429) DPP-4-Is (n1+ = 3276)
  n11 n + 1 ROR (95%CI) IC (95%CI) n11 n + 1 ROR (95%CI) IC (95%CI)
Vomiting 23 344 6.73* (4.36–10.39) 2.32* (1.69–2.94) 12 344 0.39 (0.22–0.70) −1.21 (−2.03 – −0.39)
Nausea 17 310 5.37* (3.26–8.85) 2.02* (1.31–2.73) 9 310 0.32 (0.17–0.63) −1.44 (− 2.37 – − 0.52)
Impaired gastric emptying 1 3 44.93* (4.07–496.40) 0.94 (− 1.57–3.44) 0 3
Oesophageal ulcer 1 18 5.28(0.70–39.79) 0.72 (− 1.42–2.87) 0 18
Gastrooesophageal reflux disease 1 24 3.90 (0.53–28.98) 0.65 (− 1.48–2.77) 6 18 3.63* (1.44–9.15) 1.17 (− 0.06–2.41)
Dysphagia 1 28 3.33 (0.45–24.53) 0.60 (−1.52–2.71) 5 28 2.37 (0.90–6.23) 0.80 (−0.49–2.10)
Abdominal distension 1 33 2.81 (0.38–20.58) 0.54 (− 1.56–2.64) 1 33 0.34 (0.05–2.49) −0.95 (−3.05–1.15)
Erosive oesophagitis 0 25 1 25 0.45 (0.06–3.35) − 0.67 (− 2.79–1.44)
Dyspepsia 0 45 1 45 0.25 (0.03–1.79) −1.29(− 3.37–0.80)
  1. AE adverse event, GERD gastroesophageal reflux disease, GLP-1-RAs glucagon-like peptide-1 receptor agonists, DDP-4-Is dipeptidyl peptidase-4 inhibitors, n11 the number of target drug induced GERD-like symptoms, n1+ the number of target drug induced all adverse events, n + 1 the number of all drug induced target adverse events, ROR reporting odds ratio, IC information component
  2. * signal detection
\